Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO VULVA-01: Pembrolizumab plus Lenvatinib in vulvar cancer patients
2023-509180-24-00Phase 2Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and lenvatinib in Vulval carcinoma, vulvar squamous cell carcinoma (VSCC), vulvar adenocarcinoma and 1 more (3 cohorts), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoints: Objective response rate (ORR) and Safety profile of pembrolizumab plus lenvatinib. Planned start Sep 2025; status: authorised.
02
Drugs
pembrolizumablenvatinib
03
Conditions
Vulval carcinomavulvar squamous cell carcinoma (VSCC)vulvar adenocarcinomavulvar adenosquamous carcinoma
Beyond the preview
Go deeper on 2023-509180-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509180-24-00.